Moderna’s COVID-19 vaccine received an emergency use permit (EUA) from the Food and Drug Administration (POM). Apparently, this vaccine requires a different storage method from the previous vaccines in Indonesia.
Citing information from the COVID-19 Task Force, Moderna is a vaccine developed from mRNA, so it requires a different storage technology from vaccines from inactivated virus platforms such as Sinovac. This vaccine needs storage facilities at a temperature of minus 20 degrees Celsius. To maintain its quality, the Moderna vaccine will be delivered to Indonesia along with its storage and distribution technology.
Moderna vaccine is the first vaccine from the mRNA platform to obtain EUA from the POM. This vaccine is an aid from the US Government which is distributed through the COVAX facility scheme.
The efficacy of Moderna’s COVID-19 vaccine for people aged 65 years and over reached 86.4 percent. Not only has good data for people with comorbidities, Head of the POM Penny K Lukito revealed that the Corona Moderna vaccine is still effective in protecting the body from the new variant of Corona.
“And also there is data showing that the efficacy is still protecting people who are not infected with COVID-19 in Alpha, Beta, Gamma virus variants, and I think we also assess that this virus variant develops,” Penny explained.
This, said Penny, was one of the considerations for BPOM to grant EUA. Moderna’s COVID-19 vaccine has also been included in the World Health Organization (WHO) emergency use listing (EUL) list.
(mul/up)
– .
